Open AccessMultisystem Inflammatory Syndrome in an Adult With COVID-19—A Trial of Anakinra
Author(s) -
Abhimanyu Aggarwal,
Ezra Cohen,
Marisol Figueira,
Vishakha Sabharwal,
Julie M. Herlihy,
Carroll Bronwen,
Elizabeth D. Barnett,
Stephen I. Pelton,
Ingrid Camelo
Publication year - 2021
Publication title -
infectious diseases in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.145
H-Index - 21
eISSN - 1536-9943
pISSN - 1056-9103
DOI - 10.1097/ipc.0000000000001028
Subject(s) - medicine , anakinra , kawasaki disease , myocarditis , toxic shock syndrome , macrophage activation syndrome , coronavirus , immunology , myopericarditis , abdominal pain , septic shock , pandemic , shock (circulatory) , tocilizumab , pediatrics , sepsis , disease , covid-19 , staphylococcus aureus , infectious disease (medical specialty) , artery , biology , bacteria , genetics
COVID-19 disease has been a pandemic caused by a β-coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A life-threatening multisystem inflammatory syndrome (MIS), secondary to SARS-CoV-2 virus infection, sharing common features with Kawasaki disease shock syndrome, staphylococcal/streptococcal shock syndrome, and macrophage activation syndrome in pediatric patients has been described. A total of 27 cases in adults (MIS-A) with a similar presentation have been reported so far. Here we describe the case of a 21-year-old man admitted with abdominal pain, diarrhea, tachycardia, and low blood pressure. He had elevated troponin, ferritin, and interleukin-2 receptor levels and had evidence of myocarditis. He tested positive for SARS-CoV-2 IgG antibody, and a diagnosis of MIS-A was made. Our case adds to the scant literature on this topic, and to our knowledge, it is the first case where anakinra was administered. He recovered well. MIS-A should be considered when young adults present with multiorgan dysfunction.